{"schema":"sb.node.v1","id":"sb:e/951a83d87aaa075a9b41b308","kind":"entity","label":{"text":"merck","locale":"en"},"identity":{"anchor":"label:en:merck","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy f22bd66b225b3901cd1996e08079b5893bdf41be"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":175,"separatePublishers":59,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-05","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.24: about 76% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma"],"activeDays":41,"assertions":{"regulatory-approval":16,"acquisition":5,"meeting-visit":4,"award":4,"election":4,"launch-release":4}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/41229738e82e9e53bfda1e23","kind":"observation","label":"AllSci News · 2026-10-08 · Tempus expands role in Moderna and Merck's personalized cancer vaccine commercialization push","url":"https://allsci.com/news/biotech/personalized-cancer-vaccine-tempus-expands-role/"},{"id":"sb:o/c4c4222019d22e891ac1b898","kind":"observation","label":"24/7 Wall St. · 2026-10-08 · HP, Merck, and Seagate Just Paid Their Shareholders. Here’s What Landed in Their Accounts.","url":"https://247wallst.com/investing/2026/10/08/hp-merck-and-seagate-just-paid-their-shareholders-heres-what-landed-in-their-accounts/"},{"id":"sb:o/1697376aa924a9a7a2ffa3ee","kind":"observation","label":"STAT News · 2026-10-07 · STAT+: Merck suffers a setback in Europe over its new Keytruda formulation","url":"https://www.statnews.com/pharmalot/2026/10/07/merck-suffers-setback-in-europe-over-new-keytruda-formulation/?utm_campaign=rss"},{"id":"sb:o/2c907c7ad3cb6c79e4e45852","kind":"observation","label":"Fierce Pharma · 2026-10-07 · Halozyme stymies subcutaneous Keytruda launch in select European countries as Merck vows to fight patent claims","url":"https://www.fiercepharma.com/pharma/halozyme-stymies-subq-keytruda-launch-select-european-countries-merck-vows-fight-patent"},{"id":"sb:o/726a2d2b8d23bb7e8c98ffbf","kind":"observation","label":"BioPharma Dive · 2026-10-07 · Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial","url":"https://www.biopharmadive.com/news/halozyme-merck-europe-enliven-insmed-rougetx-kymathera/832282/"},{"id":"sb:o/17768d62367c05949142174a","kind":"observation","label":"STAT News · 2026-10-06 · STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market","url":"https://www.statnews.com/2026/10/05/vaxcyte-pneumococcal-vaccine-study-pfizer-merck/?utm_campaign=rss"},{"id":"sb:o/ec1c9ebfd758dd1abb25d8dd","kind":"observation","label":"AllSci News · 2026-10-02 · Merck’s tulisokibart delivers first positive Phase II anti-TL1A data in dermatology","url":"https://allsci.com/news/clinical-trials/tulisokibart-hidradenitis-suppurativa-mercks/"},{"id":"sb:o/2d826aa152f0d0c7a6af75d0","kind":"observation","label":"Fierce Pharma · 2026-10-02 · Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS","url":"https://www.fiercepharma.com/pharma/astrazeneca-2b-bet-ivonescimab-novo-buys-hengrui-glp-1-merck-doubles-down-kras"},{"id":"sb:o/b1bd7bf898b71c80b01e8882","kind":"observation","label":"STAT News · 2026-09-30 · STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more","url":"https://www.statnews.com/pharmalot/2026/09/29/novo-licenses-obesity-pill-from-china-merck-pulls-antibiotic/?utm_campaign=rss"},{"id":"sb:o/77c9c51058d2294352360b52","kind":"observation","label":"Fierce Biotech · 2026-09-30 · Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial","url":"https://www.fiercebiotech.com/biotech/mercks-anti-tl1a-antibody-secures-win-ph-2-hidradenitis-suppurativa-trial"}],"cursor":"c1.eyJpZCI6InNiOmUvOTUxYTgzZDg3YWFhMDc1YTliNDFiMzA4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (52 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9bf494f15c0c284c8c8431d1"},{"kind":"relation","label":"co-mentioned with amgen (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dfea7994dfc1bf2dbba07eef"},{"kind":"relation","label":"co-mentioned with ai (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb6341db56b8dbbca6a242bd"},{"kind":"relation","label":"co-mentioned with china (36 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f252ac5442bd3b961c239de5"},{"kind":"relation","label":"co-mentioned with pfizer (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c8e6eba6de4f70a02bfedd7d"},{"kind":"relation","label":"co-mentioned with astrazeneca (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/42ee49b3cc5e168f2c141558"},{"kind":"relation","label":"co-mentioned with eli lilly (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0d80de6f51383d08eba9a415"},{"kind":"relation","label":"co-mentioned with novartis (31 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/400199caf0c61a6978b10108"},{"kind":"relation","label":"co-mentioned with studie (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/396a8ac749c03b6afa729bbb"},{"kind":"relation","label":"co-mentioned with roche (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/29d0fb86e64d037d03660232"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/951a83d87aaa075a9b41b308","mcp":"traverse {\"id\":\"sb:e/951a83d87aaa075a9b41b308\"}","page":"/entity/merck/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/951a83d87aaa075a9b41b308\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/951a83d87aaa075a9b41b308\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/951a83d87aaa075a9b41b308\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/951a83d87aaa075a9b41b308\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}